Medtronic announces Infuse spine trial

Medtronic (NYSE:MDT) said today that it won FDA approval for a clinical trial of its Infuse bone graft in transforaminal lumbar interbody fusion spine procedures.

The Minneapolis-based company started recruiting for the prospective, randomized pivotal trial, which is slated to enroll up to 1,000 patients. The TLIF trial would be the second clinical trial for Infuse, after the FDA approved a separate study in 2017 for posterolateral fusion procedures, which is still enrolling patients. If you want to read more about this news, click here.